DOTA-TOC in Metastasized Neuroendocrine Tumors

• Status: Completed
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators aim to explore the efficacy of [90Y-DOTA]-TOC and [177LuDOTA]-TOC therapy in advanced neuroendocrine cancer. Therefore, the investigators assess response, survival and long-term safety profile of systemic [90Y-DOTA]-TOC and [177LuDOTA]-TOC treatment in metastasized neuroendocrine cancer patients. Adverse events are assessed according to the criteria of the National Cancer Institute. Survival analyses are performed using multiple regression models.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Basel, Switzerland
• Treatments: Octreotide; Somatostatin

Criteria

Inclusion Criteria:

• histologically confirmed neuroendocrine cancer

• stage IVc disease by definition of the American Joint Committee on Cancer, i.e. occurrence of distant metastases

• visible tumor uptake in the pretherapeutic somatostatin receptor subtype 2 scintigraphy (111In-Octreoscan)

Exclusion Criteria:

• concurrent anti-tumor treatment

• secondary malignancies

• pregnancy

• breast-feeding

• incontinence

• severe concomitant illness including severe psychiatric disorders